HER2 Positive Metastatic Breast Cancer Research Update - Metastatic Breast Cancer Trial Talk

Research News

The treatment landscape for HER2 positive metastatic breast cancer has been rapidly evolving. Since February, the FDA has approved three new drugs to treat it: neratinib, tucatinib, and trastuzumab deruxtecan. More continue to look promising in clinical trials. Targeted therapies’ drugs that can attach to certain features of cancer cells have created more research avenues and may potentially lead to more treatment options.

To learn more about what it means to be HER2 positive, how the subtype is typically treated, the latest news in research, and what might be coming down the line, check out the information below.

What Does HER2 Positive Mean?
  • Breast Cancer HER2 Status  The American Cancer Society describes, in simple terms, what HER2 positive means and what test doctors use to determine whether a tumor is HER2 positive or HER2 negative.
How HER2 Positive is Typically Treated 
What’s New in HER2 Positive MBC
What’s in the Pipeline?
  • Emerging Areas in Metastatic Breast Cancer Treatment  Susan G. Komen breaks down treatments on the rise and under study for metastatic breast cancer. For HER2 positive disease, the most helpful sections are HER2 Targeted Therapies, HER2 antibody drug conjugates, and Tyrosine kinase inhibitors.
  • Clinical Trials for HER2 Positive MBC Metastatic Trial Search provides a list of over 100 clinical trials for people with HER2 positive metastatic breast cancer.

See all articles on this site tagged with HER2 Positive breast cancer

Last Modified on February 25, 2021



for past articles or specific information.